Shots:

• The P-III CLL-14 study involves assessing of Venclexta (venetoclax) + Gazyva (obinutuzumab) vs Gazyva + chlorambucil in 432 1L CLL patients
• The study included 1EP as PFS and 2EP as OR- CR- DOR- OS and demonstrated reduction in risk of disease worsening or death with no new safety signals observed. The study is conducted in collaboration with German CLL Study Group (GCLLSG)
• Venclexta/Venclyxto is a novel inhibitor of B-cell lymphoma-2 (BCL-2) protein- jointly developed & commercialized by Roche& Abbvie in the US. Gazyva/Gazyvaro is a mAb used to bind CD20 and approved in 90 countries with chlorambucil for CLL

Ref: Roche | Image: Roche